ATLANTA, May 13, 2011 /PRNewswire/ -- To mark HIV Vaccine Awareness Day on May 18, Dr. Harriet L. Robinson, CSO of GeoVax Labs, Inc. (OTCBB: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has written an article for The Scientist outlining recent progress toward the development of an effective HIV vaccine.
The article, titled “Progress toward an HIV/AIDS vaccine: Recent successes and ongoing efforts to develop a successful vaccine,” was published on The Scientist‘s website on May 11. Dr. Robinson first reviews a collaborative effort based in Thailand that culminated in 2009 with the first encouraging results from an HIV vaccine efficacy trial. She then summarizes ongoing work at GeoVax involving a combination DNA-vaccinia virus vaccine. The article concludes with a brief look at several other companies’ efforts toward a vaccine.
“As we reflect on the past progress that has been made to develop an HIV/AIDS vaccine and look to the future advancements of these efforts, we have cause for optimism,” writes Dr. Robinson in the article. “Tremendous progress has been, and is continuing to be made.”
To read the article in its entirety, please visit:
http://www.the-scientist.com/news/display/58167/
About GeoVax Labs
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. GeoVax’s vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines’ safety. Successful results from Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax’s Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America. Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV. For more information, please visit www.geovax.com
Forward-Looking Statements
Certain statements in this document are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: HVTN will commence, complete enrollment, and generate data regarding GeoVax vaccine clinical trials as and when expected, GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax’s vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective, less costly, or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax’s filings with the Securities and Exchange Commission including those set forth at “Risk Factors” in GeoVax’s Form 10-K.
Contact:
The Investor Relations Group
212-825-3210
Investor Relations:
James Carbonara
or
Public Relations:
Janet Vasquez
SOURCE GeoVax Labs, Inc.